
About Shivalik Rasayan Limited
Shivalik Rasayan Limited is a publicly listed company based in Delhi (India) founded in 1979. Shivalik Rasayan Limited is engaged in manufacturing APIs and agrochemicals. It operates on a B2B2C and Reseller / Distribution model. The company has 341 employees. Its Indian entity Shivalik Rasayan Limited reported revenue of βΉ372 Cr. Shivalik Rasayan Limited offers products and services including Active Pharmaceutical Ingredients (APIs), Agrochemicals, and Specialty Chemicals. Its focus areas include Pharmaceuticals, Active Pharmaceutical Ingredients, Agriculture and Agrochemicals.
Company details
Shivalik Rasayan Limited is involved in the production of active pharmaceutical ingredients (APIs) and agrochemicals. Operations are focused on oncology and non-oncology APIs, alongside specialty chemicals for industrial use. Facilities are established in compliance with global standards like USFDA and EDQM. The company is also dedicated to research and development in custom manufacturing. Solutions are provided across healthcare, agriculture, and chemical sectors. Innovation is emphasized to enhance product effectiveness and sustainability.
- Headquarters Delhi, India
- Employees 341
- Stage Public
- SectorsHealthcare
- Phoneβ’β’β’β’ β’β’β’β’
- Website shivalikrasayan.com
- Legal Name Shivalik Rasayan Ltd
- Market Cap₹489 Cr
SHIVALIK · NSE
- Share Price₹291.30
-4.54% today
- Revenue₹368 Cr
FY 2025-26 · +18.0% YoY
- EBITDA₹45.76 Cr
Margin 12.4%
- Net Profit₹12.13 Cr
FY 2025-26 · -27.4% YoY
- P/E (TTM)35.8x
P/B 0.8x
- ROE3.2%
ROCE 4.7%
- Debt / Equity0.20
Interest cover 38.6x
- Employee Count341
Associated legal entities of Shivalik Rasayan Limited
Shivalik Rasayan Limited operates through Shivalik Rasayan Limited, a listed company (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Shivalik Rasayan Limited Listed CIN L24237UR1979PLC005041 | Active | 16 Mar 1979 | Dehradun, Uttarakhand | ₹372 Cr | 341 | 12 | View details |
Products & Services of Shivalik Rasayan Limited
Shivalik Rasayan Limited offers a comprehensive portfolio of products and services, including Active Pharmaceutical Ingredients (APIs), Agrochemicals, and Specialty Chemicals.
Manufactured APIs adhering to global regulatory standards.
Developed agrochemicals for sustainable and effective farming.
Innovated specialty chemicals for various industrial applications.
Board of directors of Shivalik Rasayan Limited (Shivalik Rasayan Limited)
Shivalik Rasayan Limited is the primary company behind Shivalik Rasayan Limited. The board of Shivalik Rasayan Limited currently have 10 directors; the longest-serving is Suresh Kumar Singh, appointed in 1997. 12 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Suresh Kumar Singh DIN 00318015 | Whole-time director | 15 Dec 1997 | 28 yrs 11 mo | Shivalik Rasayan Limited |
| Rahul Bishnoi DIN 00317960 | Director | 23 Feb 2002 | 24 yrs 8 mo | Shivalik Rasayan Limited |
| Ashwani Kumar Sharma DIN 00325634 | Director | 18 Jul 2003 | 23 yrs 3 mo | Shivalik Rasayan Limited |
| Sumita Dwivedi DIN 08218640 | Director | 13 Nov 2018 | 8 yrs | Shivalik Rasayan Limited |
| Vimal Kumar Shrawat DIN 08274190 | Managing Director | 17 Nov 2018 | 7 yrs 11 mo | Shivalik Rasayan Limited |
| Sangeeta Bishnoi DIN 08288998 | Director | 11 Feb 2019 | 7 yrs 9 mo | Shivalik Rasayan Limited |
| Ravi Kumar Bansal DIN 08462513 | Director | 14 Aug 2019 | 7 yrs 3 mo | Shivalik Rasayan Limited |
| Shaival Saurabh DIN 01971944 | Director | 13 Aug 2024 | 2 yrs 3 mo | Shivalik Rasayan Limited |
| Sham Goel DIN 02183287 | Director | 13 Aug 2024 | 2 yrs 3 mo | Shivalik Rasayan Limited |
| Ramit Madan DIN 08071919 | Director | 13 Aug 2024 | 2 yrs 3 mo | Shivalik Rasayan Limited |
IPO & Listings of Shivalik Rasayan Limited
Shivalik Rasayan Limited is a publicly listed company on the NSE with ticker symbol SHIVALIK in India, operating in the Process industries sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date09 Dec 2021
- Listed onNSE: SHIVALIK
- Listed entityShivalik Rasayan Ltd
- Exchange sectorProcess industries
- ISININE788J01021
- Share price₹356.80 (+0.1% on the day) · 2026-10-14
- Market capitalisation₹562 Cr
- Price to earnings40.9
- EPS (diluted, trailing year)₹8.72
- Dividend yield0.14%
- Volume (last session)10,017
Financials of Shivalik Rasayan Limited
Exchange-reported figures of Shivalik Rasayan Limited, the listed company behind Shivalik Rasayan Limited (NSE: SHIVALIK).
Financial Highlights
FY 2025-26 Β· ConsolidatedRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 368 | 312 | 273 | 234 | 215 | 198 | 186 |
| Revenue growth | +18.0% | +14.2% | +16.4% | +9.2% | +8.7% | +6.1% | - |
| EBITDA | 45.76 | 40.89 | 40.63 | 43.46 | 47.33 | 38.41 | 28.94 |
| EBITDA margin | +12.4% | +13.1% | +14.9% | +18.5% | +22.0% | +19.4% | +15.5% |
| Profit before tax | 21.47 | 23.41 | 23.27 | 31.67 | 36.97 | 28.92 | 26.70 |
| Net profit | 12.13 | 16.70 | 12.71 | 20.76 | 25.60 | 17.59 | 14.06 |
| Net profit margin | +3.3% | +5.4% | +4.7% | +8.9% | +11.9% | +8.9% | +7.6% |
| EPS (βΉ) | 7.71 | 10.60 | 8.17 | 14.32 | 17.67 | 12.77 | 10.16 |
| Balance sheet | |||||||
| Total assets | 725 | 644 | 586 | 479 | 405 | 290 | 261 |
| Net worth | 599 | 536 | 508 | 419 | 287 | 179 | 176 |
| Total debt | 123 | 105 | 76.08 | 57.71 | 38.43 | 28.66 | 10.25 |
| Cash & bank | 34.37 | 27.97 | 37.74 | 30.67 | 70.76 | 4.77 | 9.04 |
| Net working capital | 289 | 225 | 188 | 163 | 157 | 57.55 | 90.57 |
| Cash flow | |||||||
| Cash from operations | (33.96) | (9.20) | (8.08) | (18.95) | 11.13 | 58.77 | 5.72 |
| Cash from investing | (21.23) | (21.11) | (74.31) | (70.77) | (23.36) | (65.02) | (102) |
| Cash from financing | 61.58 | 20.54 | 89.45 | 49.63 | 78.21 | 1.98 | 10.29 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 101 | 96.34 | 103 | 82.04 | 93.84 | 89.31 | 69.39 | 85.31 |
| Revenue growth (YoY) | +7.2% | +7.9% | +48.2% | -3.8% | +13.8% | +19.7% | - | - |
| Other income | 0.01 | 0.97 | 1.92 | 1.18 | 0.39 | 0.60 | 5.71 | 1.60 |
| EBITDA | 14.84 | 11.19 | 12.43 | 10.33 | 12.03 | 10.98 | 5.75 | 13.31 |
| EBITDA margin | +14.7% | +11.6% | +12.1% | +12.6% | +12.8% | +12.3% | +8.3% | +15.6% |
| Depreciation | 4.61 | 4.41 | 4.16 | 5.06 | 4.73 | 4.82 | 2.78 | 4.84 |
| Interest | 3.45 | 2.08 | 2.46 | 2.31 | 2.22 | 2.62 | 2.71 | 2.26 |
| Profit before tax | 6.79 | 5.67 | 7.73 | 4.14 | 5.47 | 4.14 | 5.97 | 7.81 |
| Tax | 1.40 | 1.16 | 0.55 | 0.46 | 1.17 | 1.32 | 0.79 | 0.89 |
| Net profit | 5.39 | 4.51 | 7.18 | 3.68 | 4.30 | 2.82 | 5.18 | 6.92 |
| EPS (βΉ) | 2.30 | 2.16 | 2.87 | 1.71 | 1.93 | 1.02 | 2.62 | 3.39 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 170 | 149 | 93.68 | 93.58 | 99.30 | 84.87 | 60.77 |
| Revenue growth | +14.1% | +59.3% | +0.1% | -5.8% | +17.0% | +39.7% | - |
| EBITDA | 26.36 | 26.47 | 17.13 | 19.12 | 23.24 | 18.74 | 9.47 |
| EBITDA margin | +15.5% | +17.7% | +18.3% | +20.4% | +23.4% | +22.1% | +15.6% |
| Profit before tax | 9.48 | 13.53 | 10.21 | 14.63 | 18.87 | 12.53 | 8.72 |
| Net profit | 8.16 | 13.87 | 8.64 | 15.12 | 19.36 | 12.67 | 8.76 |
| Net profit margin | +4.8% | +9.3% | +9.2% | +16.2% | +19.5% | +14.9% | +14.4% |
| EPS (βΉ) | 5.19 | 8.80 | 5.55 | 10.42 | 13.36 | 9.20 | 6.35 |
| Balance sheet | |||||||
| Total assets | 479 | 470 | 430 | 331 | 289 | 192 | 168 |
| Net worth | 405 | 398 | 374 | 291 | 273 | 180 | 168 |
| Total debt | 73.59 | 70.95 | 54.85 | 39.80 | 15.33 | 11.33 | 0.27 |
| Cash & bank | 3.10 | 24.21 | 22.95 | 9.89 | 66.93 | 0.88 | 5.95 |
| Net working capital | 110 | 111 | 96.87 | 70.51 | 94.60 | 8.45 | 39.66 |
| Cash flow | |||||||
| Cash from operations | (1.26) | (1.04) | (1.36) | (12.66) | 7.02 | 46.00 | (7.08) |
| Cash from investing | (18.19) | (19.71) | (68.74) | (64.89) | (16.50) | (61.28) | (64.65) |
| Cash from financing | (1.66) | 22.01 | 83.16 | 20.51 | 75.52 | 10.22 | (8.77) |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 45.80 | 48.44 | 42.17 | 35.13 | 46.67 | 46.26 | 39.78 | 40.16 |
| Revenue growth (YoY) | -1.9% | +4.7% | +6.0% | -12.5% | +23.8% | +46.5% | - | - |
| Other income | 0.02 | 0.10 | 0.18 | 0.64 | 0.02 | 0.13 | 0.48 | 1.46 |
| Total expenses | 39.64 | 41.58 | 35.18 | 29.18 | 39.79 | 39.90 | 32.42 | 33.56 |
| EBITDA | 6.16 | 6.86 | 6.99 | 5.95 | 6.88 | 6.36 | 7.36 | 6.60 |
| EBITDA margin | +13.4% | +14.2% | +16.6% | +16.9% | +14.7% | +13.7% | +18.5% | +16.4% |
| Depreciation | 2.73 | 2.63 | 2.43 | 3.24 | 2.87 | 3.01 | 2.30 | 2.63 |
| Interest | 1.76 | 1.25 | 2.07 | 1.34 | 1.23 | 1.46 | 2.06 | 1.50 |
| Profit before tax | 1.69 | 3.08 | 2.67 | 2.01 | 2.80 | 2.02 | 3.48 | 3.93 |
| Tax | 0.39 | 0.43 | (0.06) | (0.02) | 0.60 | 0.79 | 0.16 | (0.07) |
Financial Statements
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 101 | 96.34 | 103 | 82.04 | 93.84 | 89.31 | 69.39 | 85.31 |
| Revenue growth (YoY) | +7.2% | +7.9% | +48.2% | -3.8% | +13.8% | +19.7% | - | - |
| Other income | 0.01 | 0.97 | 1.92 | 1.18 | 0.39 | 0.60 | 5.71 | 1.60 |
| EBITDA | 14.84 | 11.19 | 12.43 | 10.33 | 12.03 | 10.98 | 5.75 | 13.31 |
| EBITDA margin | +14.7% | +11.6% | +12.1% | +12.6% | +12.8% | +12.3% | +8.3% | +15.6% |
| Depreciation | 4.61 | 4.41 | 4.16 | 5.06 | 4.73 | 4.82 | 2.78 | 4.84 |
| Interest | 3.45 | 2.08 | 2.46 | 2.31 | 2.22 | 2.62 | 2.71 | 2.26 |
| Profit before tax | 6.79 | 5.67 | 7.73 | 4.14 | 5.47 | 4.14 | 5.97 | 7.81 |
| Tax | 1.40 | 1.16 | 0.55 | 0.46 | 1.17 | 1.32 | 0.79 | 0.89 |
| Net profit | 5.39 | 4.51 | 7.18 | 3.68 | 4.30 | 2.82 | 5.18 | 6.92 |
| EPS (βΉ) | 2.30 | 2.16 | 2.87 | 1.71 | 1.93 | 1.02 | 2.62 | 3.39 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 368 | 312 | 273 | 234 | 215 | 198 | 186 |
| Revenue growth | +18.0% | +14.2% | +16.4% | +9.2% | +8.7% | +6.1% | - |
| Other income | 4.08 | 8.31 | 3.98 | 4.66 | 3.71 | 1.13 | 3.14 |
| Total expenses | 322 | 271 | 232 | 191 | 167 | 159 | 157 |
| Employee cost | 0.00 | 54.02 | 45.69 | 33.09 | 26.37 | 18.11 | 13.66 |
| EBITDA | 45.76 | 40.89 | 40.63 | 43.46 | 47.33 | 38.41 | 28.94 |
| EBITDA margin | +12.4% | +13.1% | +14.9% | +18.5% | +22.0% | +19.4% | +15.5% |
| Depreciation | 18.77 | 15.77 | 12.38 | 11.60 | 11.01 | 8.58 | 3.51 |
| Interest | 9.60 | 10.02 | 8.96 | 4.85 | 3.06 | 2.04 | 1.87 |
| Profit before tax | 21.47 | 23.41 | 23.27 | 31.67 | 36.97 | 28.92 | 26.70 |
| Tax | 3.51 | 2.98 | 5.15 | 1.83 | 2.71 | 4.27 | 4.65 |
| Net profit | 12.13 | 16.70 | 12.71 | 20.76 | 25.60 | 17.59 | 14.06 |
| Net profit margin | +3.3% | +5.4% | +4.7% | +8.9% | +11.9% | +8.9% | +7.6% |
| EPS (βΉ) | 7.71 | 10.60 | 8.17 | 14.32 | 17.67 | 12.77 | 10.16 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 7.88 | 7.88 | 7.78 | 7.24 | 7.24 | 6.89 | 6.89 |
| Reserves & surplus | 591 | 528 | 496 | 397 | 270 | 172 | 169 |
| Shareholders' funds (net worth) | 599 | 536 | 508 | 419 | 287 | 179 | 176 |
| Minority interest | 0.00 | 0.00 | 0.00 | 0.00 | 77.49 | 80.42 | 73.27 |
| Secured loans | 23.38 | 16.50 | 23.97 | 13.01 | 38.43 | 28.66 | 10.25 |
| Unsecured loans | 99.41 | 88.23 | 52.11 | 44.70 | 0.00 | 0.00 | 0.00 |
| Total debt | 123 | 105 | 76.08 | 57.71 | 38.43 | 28.66 | 10.25 |
| Total liabilities | 725 | 644 | 586 | 479 | 405 | 290 | 261 |
| Assets | |||||||
| Gross block | 442 | 425 | 287 | 280 | 271 | 247 | 82.63 |
| Net block | 335 | 337 | 214 | 218 | 221 | 210 | 51.57 |
| Capital work in progress | 0.00 | 0.00 | 117 | 57.34 | 3.30 | 0.00 | 102 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 147 | 118 | 102 | 74.99 | 38.14 | 9.81 | 20.12 |
| Sundry debtors | 115 | 96.12 | 86.74 | 84.77 | 70.00 | 68.84 | 58.17 |
| Cash & bank balances | 34.37 | 27.97 | 37.74 | 30.67 | 70.76 | 4.77 | 9.04 |
| Loans & advances | 85.70 | 72.85 | 67.60 | 71.12 | 60.99 | 47.29 | 70.28 |
| Total current assets | 382 | 315 | 294 | 262 | 240 | 131 | 158 |
| Total current liabilities | 93.57 | 89.97 | 106 | 98.87 | 83.11 | 73.16 | 67.04 |
| Net working capital | 289 | 225 | 188 | 163 | 157 | 57.55 | 90.57 |
| Total assets | 725 | 644 | 586 | 479 | 405 | 290 | 261 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 27.97 | 37.74 | 30.67 | 70.76 | 4.77 | 9.04 | 94.97 |
| Net cash from operating activities | (33.96) | (9.20) | (8.08) | (18.95) | 11.13 | 58.77 | 5.72 |
| Net cash from investing activities | (21.23) | (21.11) | (74.31) | (70.77) | (23.36) | (65.02) | (102) |
| Net cash from financing activities | 61.58 | 20.54 | 89.45 | 49.63 | 78.21 | 1.98 | 10.29 |
| Net change in cash | 6.40 | (9.77) | 7.07 | (40.09) | 65.99 | (4.26) | (85.93) |
| Closing cash | 34.37 | 27.97 | 37.74 | 30.67 | 70.76 | 4.77 | 9.04 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +18.0% | +14.2% | +16.4% | +9.2% | +8.7% | +6.1% | - |
| EBITDA growth | +11.9% | +0.6% | -6.5% | -8.2% | +23.2% | +32.7% | - |
| PBT growth | -14.5% | +8.0% | -26.5% | -14.3% | +27.8% | +8.3% | +2.0% |
| Net income growth | -27.4% | +31.4% | -38.8% | -18.9% | +45.5% | +25.1% | - |
| Revenue CAGR (3Y) | +16.2% | +13.2% | +11.4% | +8.0% | +8.0% | +8.4% | +14.7% |
| EBITDA CAGR (3Y) | +2.7% | -4.8% | +1.9% | +14.5% | +25.9% | +16.8% | +16.4% |
| Profitability & leverage | |||||||
| Net income margin | +4.9% | +7.1% | +6.6% | +12.7% | +16.0% | +12.5% | +11.8% |
| Return on capital employed | +4.7% | +5.4% | +6.1% | +9.1% | +14.9% | +15.6% | +15.2% |
| Return on net worth | +3.2% | +4.2% | +3.9% | +8.4% | +14.7% | +13.9% | +12.9% |
| Debt / equity | 0.20 | 0.17 | 0.14 | 0.14 | 0.14 | 0.11 | 0.09 |
| Long-term debt / equity | 0.04 | 0.04 | 0.04 | 0.03 | 0.04 | 0.04 | 0.02 |
| Interest cover | 38.62 | 33.11 | 31.72 | 15.22 | 8.43 | 6.84 | 7.35 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 0.85 | 0.88 | 0.96 | 0.85 | 0.83 | 1.20 | 2.46 |
| Inventory turnover | 2.78 | 2.84 | 3.09 | 4.14 | 8.96 | 13.20 | 8.95 |
| Debtors turnover | 3.48 | 3.41 | 3.18 | 3.03 | 3.09 | 3.11 | 3.38 |
| EPS (βΉ) | 7.87 | 10.60 | 8.17 | 14.32 | 17.67 | 12.77 | 10.16 |
| Dividend per share (βΉ) | 0.50 | 0.50 | 0.50 | 0.50 | 0.50 | 0.50 | 0.25 |
| Book value per share (βΉ) | 380.37 | 340.46 | 324.05 | 278.69 | 191.54 | 129.96 | 127.93 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 45.80 | 48.44 | 42.17 | 35.13 | 46.67 | 46.26 | 39.78 | 40.16 |
| Revenue growth (YoY) | -1.9% | +4.7% | +6.0% | -12.5% | +23.8% | +46.5% | - | - |
| Other income | 0.02 | 0.10 | 0.18 | 0.64 | 0.02 | 0.13 | 0.48 | 1.46 |
| Total expenses | 39.64 | 41.58 | 35.18 | 29.18 | 39.79 | 39.90 | 32.42 | 33.56 |
| EBITDA | 6.16 | 6.86 | 6.99 | 5.95 | 6.88 | 6.36 | 7.36 | 6.60 |
| EBITDA margin | +13.4% | +14.2% | +16.6% | +16.9% | +14.7% | +13.7% | +18.5% | +16.4% |
| Depreciation | 2.73 | 2.63 | 2.43 | 3.24 | 2.87 | 3.01 | 2.30 | 2.63 |
| Interest | 1.76 | 1.25 | 2.07 | 1.34 | 1.23 | 1.46 | 2.06 | 1.50 |
| Profit before tax | 1.69 | 3.08 | 2.67 | 2.01 | 2.80 | 2.02 | 3.48 | 3.93 |
| Tax | 0.39 | 0.43 | (0.06) | (0.02) | 0.60 | 0.79 | 0.16 | (0.07) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 170 | 149 | 93.68 | 93.58 | 99.30 | 84.87 | 60.77 |
| Revenue growth | +14.1% | +59.3% | +0.1% | -5.8% | +17.0% | +39.7% | - |
| Other income | 0.96 | 2.06 | 1.65 | 2.20 | 1.99 | 0.38 | 1.20 |
| Total expenses | 144 | 123 | 76.55 | 74.46 | 76.06 | 66.13 | 51.30 |
| Employee cost | 25.86 | 23.15 | 16.62 | 12.94 | 11.88 | 9.11 | 4.14 |
| EBITDA | 26.36 | 26.47 | 17.13 | 19.12 | 23.24 | 18.74 | 9.47 |
| EBITDA margin | +15.5% | +17.7% | +18.3% | +20.4% | +23.4% | +22.1% | +15.6% |
| Depreciation | 11.55 | 8.70 | 5.28 | 5.24 | 5.24 | 6.06 | 1.01 |
| Interest | 6.29 | 6.30 | 3.29 | 1.45 | 1.12 | 0.53 | 0.94 |
| Profit before tax | 9.48 | 13.53 | 10.21 | 14.63 | 18.87 | 12.53 | 8.72 |
| Tax | 1.32 | (0.34) | 1.57 | (0.49) | (0.49) | (0.14) | (0.04) |
| Net profit | 8.16 | 13.87 | 8.64 | 15.12 | 19.36 | 12.67 | 8.76 |
| Net profit margin | +4.8% | +9.3% | +9.2% | +16.2% | +19.5% | +14.9% | +14.4% |
| EPS (βΉ) | 5.19 | 8.80 | 5.55 | 10.42 | 13.36 | 9.20 | 6.35 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 7.88 | 7.88 | 7.78 | 7.24 | 7.24 | 6.89 | 6.89 |
| Reserves & surplus | 397 | 390 | 363 | 271 | 256 | 173 | 161 |
| Shareholders' funds (net worth) | 405 | 398 | 374 | 291 | 273 | 180 | 168 |
| Secured loans | 27.76 | 23.09 | 32.30 | 18.41 | 4.55 | 4.70 | 0.26 |
| Unsecured loans | 45.83 | 47.86 | 22.55 | 21.39 | 10.78 | 6.63 | 0.01 |
| Total debt | 73.59 | 70.95 | 54.85 | 39.80 | 15.33 | 11.33 | 0.27 |
| Total liabilities | 479 | 470 | 430 | 331 | 289 | 192 | 168 |
| Assets | |||||||
| Gross block | 298 | 286 | 150 | 149 | 146 | 132 | 24.89 |
| Net block | 250 | 250 | 122 | 126 | 128 | 120 | 17.88 |
| Capital work in progress | 0.00 | 0.00 | 117 | 57.34 | 3.30 | 0.00 | 61.24 |
| Investments | 81.09 | 74.47 | 73.43 | 64.94 | 55.01 | 53.40 | 39.32 |
| Inventories | 76.79 | 55.56 | 42.45 | 29.93 | 11.13 | 4.61 | 3.16 |
| Sundry debtors | 33.31 | 27.22 | 31.48 | 19.52 | 6.78 | 16.29 | 8.21 |
| Cash & bank balances | 3.10 | 24.21 | 22.95 | 9.89 | 66.93 | 0.88 | 5.95 |
| Loans & advances | 45.14 | 45.85 | 41.75 | 44.53 | 38.21 | 17.49 | 40.51 |
| Total current assets | 158 | 153 | 139 | 104 | 123 | 39.27 | 57.83 |
| Total current liabilities | 48.70 | 41.85 | 41.76 | 33.36 | 28.45 | 30.82 | 18.17 |
| Net working capital | 110 | 111 | 96.87 | 70.51 | 94.60 | 8.45 | 39.66 |
| Total assets | 479 | 470 | 430 | 331 | 289 | 192 | 168 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 24.21 | 22.95 | 9.89 | 66.93 | 0.88 | 5.95 | 86.45 |
| Net cash from operating activities | (1.26) | (1.04) | (1.36) | (12.66) | 7.02 | 46.00 | (7.08) |
| Net cash from investing activities | (18.19) | (19.71) | (68.74) | (64.89) | (16.50) | (61.28) | (64.65) |
| Net cash from financing activities | (1.66) | 22.01 | 83.16 | 20.51 | 75.52 | 10.22 | (8.77) |
| Net change in cash | (21.11) | 1.26 | 13.06 | (57.04) | 66.05 | (5.06) | (80.51) |
| Closing cash | 3.10 | 24.21 | 22.95 | 9.89 | 66.93 | 0.88 | 5.95 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +14.1% | +59.3% | +0.1% | -5.8% | +17.0% | +39.7% | - |
| EBITDA growth | -0.4% | +54.5% | -10.4% | -17.7% | +24.0% | +97.9% | - |
| PBT growth | -29.9% | +32.5% | -30.2% | -22.5% | +50.6% | +43.7% | +0.9% |
| Net income growth | -41.2% | +60.5% | -42.9% | -21.9% | +52.8% | +44.6% | - |
| Revenue CAGR (3Y) | +22.1% | +14.5% | +3.4% | +15.5% | +27.5% | +24.8% | +14.1% |
| EBITDA CAGR (3Y) | +11.3% | +4.4% | -3.0% | +26.4% | +54.9% | +36.9% | +11.8% |
| Profitability & leverage | |||||||
| Net income margin | +4.8% | +9.3% | +9.2% | +16.2% | +19.5% | +14.9% | +14.4% |
| Return on capital employed | +3.3% | +4.4% | +3.6% | +5.2% | +8.3% | +7.3% | +5.7% |
| Return on net worth | +2.0% | +3.6% | +2.6% | +5.4% | +8.5% | +7.3% | +5.4% |
| Debt / equity | 0.18 | 0.16 | 0.14 | 0.10 | 0.06 | 0.03 | 0.03 |
| Long-term debt / equity | 0.04 | 0.05 | 0.05 | 0.03 | 0.02 | 0.01 | 0.02 |
| Interest cover | 42.47 | 35.45 | 27.76 | 10.45 | 6.22 | 4.18 | 11.11 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 0.58 | 0.68 | 0.63 | 0.63 | 0.71 | 1.08 | 2.57 |
| Inventory turnover | 2.57 | 3.05 | 2.59 | 4.56 | 12.62 | 21.85 | 12.94 |
| Debtors turnover | 5.62 | 5.08 | 3.67 | 7.12 | 8.61 | 6.93 | 7.20 |
| EPS (βΉ) | 5.19 | 8.80 | 5.55 | 10.42 | 13.36 | 9.20 | 6.35 |
| Dividend per share (βΉ) | 0.50 | 0.50 | 0.50 | 0.50 | 0.50 | 0.50 | 0.25 |
| Book value per share (βΉ) | 256.91 | 252.47 | 238.23 | 191.82 | 181.90 | 130.63 | 121.67 |
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Shivalik Rasayan Limited (Biopharma Outsourcing & Drug Delivery) in India, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of integrated contract research development and manufacturing services | 2007 | Bengaluru, Karnataka, India | USD 35.74 M | USD 226.38 M | 2,062 | |
Pharmaceutical and biotechnology company | 2005 | Hyderabad, Telangana, India | USD 229.73 M | USD 726.15 M | 548 | |
India's leading healthcare products distribution platform | 2018 | Mumbai, Maharashtra, India | USD 59.67 M | USD 702.49 M | 557 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Shivalik Rasayan Limited
Complete news archive for Shivalik Rasayan Limited
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Shivalik Rasayan Limited
Shivalik Rasayan Limited was founded in 1979.
Shivalik Rasayan Limited is headquartered in Delhi, India. It is registered at Delhi, Delhi, India.
Shivalik Rasayan Limited has 341 employees.
The primary company behind Shivalik Rasayan Limited, Shivalik Rasayan Limited, reported revenue of βΉ372 Cr for FY 2026, up 18% year on year.
Shivalik Rasayan Limited is involved in the production of active pharmaceutical ingredients (APIs) and agrochemicals. Operations are focused on oncology and non-oncology APIs, alongside specialty chemicals for industrial use. Facilities are established in compliance with global standards like USFDA and EDQM. The company is also dedicated to research and development in custom manufacturing. Solutions are provided across healthcare, agriculture, and chemical sectors. Innovation is emphasized to enhance product effectiveness and sustainability.
Shivalik Rasayan Limited offers Active Pharmaceutical Ingredients (APIs), Agrochemicals, and Specialty Chemicals.
Yes, Shivalik Rasayan Limited is publicly traded on NSE under the ticker symbol SHIVALIK.
Shivalik Rasayan Limited operates through Shivalik Rasayan Limited.
The legal entities of Shivalik Rasayan Limited currently have 12 directors, including Sangeeta Bishnoi, Sumita Dwivedi, Ravi Kumar Bansal and others.
